Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for naproxen
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on naproxen or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on naproxen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Naproxen Top results for naproxen - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for naproxen The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory
A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain 29089169 2017 12 19 1097-6760 2017 Oct 28 Annals of emergency medicine Ann Emerg Med A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. S0196-0644(17)31700-6 10.1016/j.annemergmed.2017.09.031 In US emergency departments (EDs), patients with low back pain are often treated (...) with nonsteroidal anti-inflammatory drugs and muscle relaxants. We compare functional outcomes among patients randomized to a 1-week course of naproxen+placebo versus naproxen+orphenadrine or naproxen+methocarbamol. This was a randomized, double-blind, comparative effectiveness trial conducted in 2 urban EDs. Patients presenting with acute, nontraumatic, nonradicular low back pain were enrolled. The primary outcome was improvement on the Roland-Morris Disability Questionnaire (RMDQ) between ED discharge and 1 week later. All patients
Pre-Operative Naproxen for Gynecological Surgery: Clinical Effectiveness Pre-Operative Naproxen for Gynecological Surgery: Clinical Effectiveness | CADTH.ca Find the information you need Pre-Operative Naproxen for Gynecological Surgery: Clinical Effectiveness Pre-Operative Naproxen for Gynecological Surgery: Clinical Effectiveness Published on: July 24, 2017 Project Number: RB1123-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What (...) is the clinical effectiveness of pre-operative administration of naproxen to reduce post-operative pain following gynecological surgery? Key Message No relevant literature was identified regarding the clinical effectiveness of pre-operative administration of naproxen to reduce post-operative pain following gynecological surgery. Tags cancer, neuroendocrine tumors, somatostatin, Tumour, Tumours, neuroendocrinology, somatuline, peptide receptor radiotherapy Files Rapid Response Summary of Abstracts Published
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. BACKGROUND: Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require non-steroidal anti-inflammatory drugs (NSAIDs). We hypothesised that a cyclooxygenase-2-selective NSAID plus proton (...) staff member randomly assigned (1:1) patients who were negative for Helicobacter pylori with a computer-generated list of random numbers to receive oral administrations of either celecoxib 100 mg twice per day plus esomeprazole 20 mg once per day or naproxen 500 mg twice per day plus esomeprazole 20 mg once per day for 18 months. All patients resumed aspirin 80 mg once per day. Both patients and investigators were masked to their treatments. The primary endpoint was recurrent upper gastrointestinal
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. BACKGROUND: The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal antiinflammatory drugs (NSAIDs), remains uncertain. METHODS: Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen. The goal of the trial was to assess the noninferiority of celecoxib with regard (...) , 209±37 mg), the naproxen group (852±103 mg), or the ibuprofen group (2045±246 mg) for a mean treatment duration of 20.3±16.0 months and a mean follow-up period of 34.1±13.4 months. During the trial, 68.8% of the patients stopped taking the study drug, and 27.4% of the patients discontinued follow-up. In the intention-to-treat analyses, a primary outcome event occurred in 188 patients in the celecoxib group (2.3%), 201 patients in the naproxen group (2.5%), and 218 patients in the ibuprofen group
Naproxen, paracetamol and pamabrom versus paracetamol, pyrilamine and pamabrom in primary dysmenorrhea: a randomized, double-blind clinical trial. 27813503 2016 11 04 2017 01 19 0717-6384 16 9 2016 Oct 24 Medwave Medwave Naproxen, paracetamol and pamabrom versus paracetamol, pyrilamine and pamabrom in primary dysmenorrhea: a randomized, double-blind clinical trial. e6587 10.5867/medwave.2016.09.6587 Dysmenorrhea is caused by the discharge of prostaglandins into the uterine tissue; therefore (...) of the combinations is widely used in Mexico (paracetamol, pyrilamine and pamabrom) and the selected comparison was a medication with naproxen sodium, paracetamol and pamabrom based on the pathophysiology of primary dysmenorrhea. This was a single-centre, double blind, experimental, parallel group, randomized trial. Female patients with primary dysmenorrhea, older than 17 years and with pain intensity greater than 45 mm on a visual analogue scale, were included. The patients were then randomized to receive
Naproxen (Stirlescent) - treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults Published 13 June 2106 Product Update: naproxen 250mg effervescent tablets (Stirlescent ® ) SMC No. (1154/16) Stirling Anglian Pharmaceuticals Ltd. 06 May 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs (...) ) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission naproxen 250mg effervescent tablets (Stirlescent ® ) are accepted for restricted use within NHS Scotland. Indication under review: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults. SMC restriction: use in patients unable to swallow naproxen tablets. Naproxen 250mg effervescent tablets (Stirlescent
Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. 26501533 2015 10 27 2015 11 04 2016 10 17 1538-3598 314 15 2015 Oct 20 JAMA JAMA Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. 1572-80 10.1001/jama.2015.13043 Low back pain (LBP) is responsible for more than 2.5 million visits to US emergency departments (EDs) annually. These patients (...) are usually treated with nonsteroidal anti-inflammatory drugs, acetaminophen, opioids, or skeletal muscle relaxants, often in combination. To compare functional outcomes and pain at 1 week and 3 months after an ED visit for acute LBP among patients randomized to a 10-day course of (1) naproxen + placebo; (2) naproxen + cyclobenzaprine; or (3) naproxen + oxycodone/acetaminophen. This randomized, double-blind, 3-group study was conducted at one urban ED in the Bronx, New York City. Patients who presented
Naproxen USE OF NAPROXEN IN PREGNANCY 0344 892 0909 USE OF NAPROXEN IN PREGNANCY (Date of issue: August 2013 , Version: 1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Naproxen is a non-steroidal anti-inflammatory drug used primarily (...) for the treatment of pain and inflammation in rheumatic disease and other musculoskeletal disorders. Few studies have specifically investigated the fetal risks of maternal naproxen use in pregnancy. Some studies on NSAIDs as a class have shown an association between use in pregnancy and an increased risk of cardiovascular defects in the offspring, as well as an increased risk of spontaneous abortion. Increased rates of orofacial clefts, cardiac defects and non-isolated anophthalmia/microphthalmia have been
Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine 22585767 2012 06 04 2012 08 07 2013 11 21 1098-4275 129 6 2012 Jun Pediatrics Pediatrics Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. e1411-20 10.1542/peds.2011-2455 Treatment of adolescent migraine remains a significant unmet medical need. We compared the efficacy and safety of 3 doses of sumatriptan and naproxen sodium (suma/nap) combination tablets to placebo (...) Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't 2012 05 14 United States Pediatrics 0376422 0031-4005 0 Placebos 57Y76R9ATQ Naproxen 8R78F6L9VO Sumatriptan AIM IM J Pediatr. 2012 Nov;161(5):969-70 23095698 Adolescent Child Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Female Humans Male Migraine Disorders drug therapy epidemiology pathology Naproxen administration & dosage Pain Measurement drug effects Placebos Single-Blind Method
Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial 22055339 2012 01 30 2012 07 19 2016 12 15 1097-6868 206 2 2012 Feb American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. 129.e1-8 10.1016/j.ajog.2011.09.021 The purpose of this study was to evaluate whether oral naproxen or transdermal (...) estradiol decreases bleeding and spotting in women who are initiating the levonorgestrel-releasing intrauterine system. We conducted a randomized controlled trial of naproxen, estradiol, or placebo that was administered over the first 12 weeks of levonorgestrel-releasing intrauterine system use. Participants completed a written bleeding diary. We imputed missing values and performed an intention-to-treat analysis. There were 129 women who were assigned randomly to naproxen (n = 42 women), estradiol (n
Oxaprozin and Naproxen Sodium Postoperatively Reduce Pain After Removal of Impacted Third Molars UTCAT873, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Oxaprozin and Naproxen Sodium Post-operatively Reduce Pain After Removal of Impacted Third Molars Clinical Question In adult patients having extraction of impacted third molars, do oxaprozin or naproxen prevent or reduce pain better than does placebo? Clinical Bottom (...) Line 1,200 mg oxaprozin or 550 mg naproxen sodium daily for one week reduce postoperative pain after extraction of impacted third molars better than does placebo, but do not exceed placebo for swelling. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Kara 2010 36 healthy adults 18-25 yrs RCT, double-blind, crossover Key results Both oxaprozin and naproxen sodium provided
Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan 20303198 2010 07 12 2010 08 05 2016 11 22 1097-6760 56 1 2010 Jul Annals of emergency medicine Ann Emerg Med Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. 7-17 10.1016/j.annemergmed.2010.02.005 Multiple parenteral medications are used to treat migraine and other acute primary headaches (...) in the emergency department (ED). Regardless of specific headache diagnosis, no medication eliminates the frequent recurrence of primary headache after ED discharge. It is uncertain which medication primary headache patients should be given on discharge from an ED. The aim of this study is to compare the efficacy of oral sumatriptan with naproxen for treatment of post-ED recurrent primary headache. This was a randomized, double-blind efficacy trial. We randomized patients to either naproxen 500
Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B CRD summary This review concluded that naproxen sodium was more effective than placebo, but might produce more adverse events, in the acute (...) treatment of moderate or severe migraine attacks in adults. Trials were needed to compare it with other active treatments. These conclusions reflect the results, but the small number of trials and omission of the trial selection process should be considered. Authors' objectives To determine the efficacy and safety of naproxen sodium in the treatment of acute migraine. Searching MEDLINE, EMBASE, EBM reviews, and the Cochrane Library were searched, without language restriction, for articles from
Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life 19486178 2009 07 08 2009 10 08 2013 11 21 1526-4610 49 7 2009 Jul Headache Headache Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. 971-82 10.1111/j.1526-4610.2009.01458.x To evaluate efficacy and tolerability of a single, fixed-dose tablet of sumatriptan 85 mg/naproxen sodium 500 mg (sumatriptan/naproxen sodium) vs placebo in migraineurs who had discontinued (...) treatment with a short-acting triptan because of poor response or intolerance. Triptan monotherapy is ineffective or poorly tolerated in 1 of 3 migraineurs and in 2 of 5 migraine attacks. In April, 2008, the Food and Drug Administration approved the combination therapy sumatriptan/naproxen sodium, developed specifically to target multiple migraine mechanisms. This combination product offers an alternative migraine therapy for patients who have reported poor response or intolerance to short-acting
Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI 18653484 2009 05 13 2009 06 24 2016 11 25 1468-2060 68 6 2009 Jun Annals of the rheumatic diseases Ann. Rheum. Dis. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using (...) quantitative MRI. 938-47 10.1136/ard.2008.088732 In a multicentre study to explore the effects of licofelone as a disease-modifying osteoarthritis drug in comparison with naproxen in patients with knee osteoarthritis (OA), using MRI and x-ray examination. Patients with knee OA (n = 355) were randomised to receive either licofelone (200 mg twice a day) or naproxen (500 mg twice a day). MRI and x-ray examinations were performed at baseline, 6 months (MRI only), 12 and 24 months. MRI was used to assess
Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine 18606965 2008 07 08 2008 07 22 2013 11 21 1526-632X 71 2 2008 Jul 08 Neurology Neurology Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. 114-21 10.1212/01.wnl.0000316800.22949.20 Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome. To investigate the efficacy and tolerability of a fixed (...) -dose, single-tablet formulation of sumatriptan 85 mg, formulated with RT Technology, and naproxen sodium 500 mg (sumatriptan/naproxen) as early intervention acute therapy for migraine. Patients (aged 18 to 65 years) with International Headache Society-defined migraine with or without aura were enrolled in one of two identically designed, randomized, double-blind, parallel group, placebo-controlled studies. Patients treated a single migraine within 1 hour of onset of migraine head pain and while